<DOC>
	<DOCNO>NCT00820053</DOCNO>
	<brief_summary>The aim study analyze therapeutic effect adjuvant TACE resection.Patients receive curative resection ( R0 ) randomize postoperative TACE group TACE group . The time recurrence , overall survival well incidence complication therapy observed confirm role adjuvant TACE .</brief_summary>
	<brief_title>A Trial Adjuvant Transarterial Chemoembolization ( TACE ) Preventing Tumor Recurrence After Liver Resection</brief_title>
	<detailed_description>Although resection hepatocellular carcinoma potentially curative , local recurrence common recurrence rate high 50 % 5 year . So reduce recurrence rate HCC , intervention try clinic , include transarterial chemoembolization ( TACE ) , immunotherapy , interferon treatment etc . But adjuvant therapy prove effective long term efficacy clinical application remain explored . TACE prove effective patient advance stage HCC randomize control trial meta-analysis , role adjuvant TACE liver resection controversial . The result get different randomize control trial vary significantly bias patient selection , different study design，the small size sample , different drug use chemotherapy lack proper stratification… , big sample size , well patient select well design randomize control trial need confirm role postoperative TACE . Patients HCC receive curative liver resection ( R0 ) randomly assign 1:1 doctor receive adjuvant TACE ( control group ) TACE ( treatment group ) . All patient treatment group receive adjuvant TACE 45 day liver resection . The outcomes patient evaluate 3-years follow .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>1 . Male female patient &gt; 18 year &lt; =70 year age . 2 . Patients HCC receive curative liver resection ( R0 ) . 3 . Criteria liver function : Child AB level , serum bilirubin ≤ 1.5 time upper limit normal value , alanine aminotransferase aspartate aminotransferase ≤ 2 time upper limit normal value . 4 . No dysfunction major organ ; Blood routine , kidney function , cardiac function lung function basically normal . Hb ≥90g/L , WBC ≥3.000 cells/mm³ , platelet ≥80.000 cells/mm³ . 5 . Karnofsky Performance Score performance 60 . 6 . Patients understand trial sign information consent 1 . Patients apparent cardiac , pulmonary , cerebronic renal dysfunction , may affect treatment liver cancer . 2 . Patients disease may affect treatment mention . 3 . Patients medical history malignant tumor . 4 . Subjects participate clinical trial . 5 . Extrahepatic metastasis , portal vein major vascular involvement . liver function : Child C. 6 . Patients would sign consent trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>TACE</keyword>
	<keyword>time recurrence</keyword>
	<keyword>overall survival</keyword>
</DOC>